Pathway-Enriched Gene Signature Associated with 53BP1 Response to PARP Inhibition in Triple-Negative Breast Cancer

Abstract excerpt

Abstract Effective treatment of patients with triple-negative (ER-negative, PR-negative, HER2-negative) breast cancer remains a challenge. Although PARP inhibitors are being evaluated in clinical trials, biomarkers are needed to identify patients who will most benefit from anti-PARP therapy. We determined the responses of three PARP inhibitors (veliparib, olaparib, and talazoparib) in a panel of eight...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to DNA Repair Mechanisms
• Share to Integrated Circuits and Semiconductor Failure Analysis
• Share to PARP inhibition in cancer therapy